Actively Recruiting
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-03-24
148
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
CONDITIONS
Official Title
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Diagnosis of diffuse large B-cell lymphoma by pathology using WHO 2016 criteria
- Molecular subtype categorized as "Other" by high-throughput sequencing of tissue or blood
- Immunohistochemistry showing MYC expression 6% and BCL2 expression 50%
- At least one measurable lesion on CT or MRI with a size of 1.5 cm or larger
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Liver function within specified limits: total bilirubin 6 times normal, ALT and AST 5 times normal, ALP 5 times normal
- Kidney function adequate with serum creatinine 1.5 times normal or creatinine clearance 35 mL/min or more
- Voluntary agreement to participate with signed informed consent
You will not qualify if you...
- Currently enrolled in another clinical trial
- Previous lymphoma treatment with other regimens before this study
- Presence of other active malignant tumors
- Deemed ineligible by investigator judgment
- Severe psychiatric or neurological disorders affecting consent or reporting
- Unable to follow study visits and monitoring
- Pregnant or breastfeeding, or unwilling to use contraception if able to become pregnant
- Active infection or uncontrolled hepatitis B or hepatitis C virus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210000
Actively Recruiting
Research Team
W
Wei Xu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here